Carpenter Technology Corporation logo

Carpenter Technology Corporation (CRS)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
557. 77
+3.37
+0.6079%
$
28.67B Market Cap
- P/E Ratio
0.8% Div Yield
757,300 Volume
- Eps
$ 554.4
Previous Close
Add Transaction
Day Range
532.58 560.05
Year Range
228 625.99
Want to track CRS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Best Momentum Stocks to Buy for July 16th

Best Momentum Stocks to Buy for July 16th

NBR, CRS and TROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 16, 2026.

Zacks | 2 days ago
Why Carpenter Technology (CRS) is a Top Momentum Stock for the Long-Term

Why Carpenter Technology (CRS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 5 days ago
Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?

Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?

Here is how Carpenter Technology (CRS) and Element Solutions (ESI) have performed compared to their sector so far this year.

Zacks | 6 days ago
Carpenter Technology (CRS) Crossed Above the 20-Day Moving Average: What That Means for Investors

Carpenter Technology (CRS) Crossed Above the 20-Day Moving Average: What That Means for Investors

After reaching an important support level, Carpenter Technology (CRS) could be a good stock pick from a technical perspective. CRS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Zacks | 1 week ago
Can CRS Achieve Its Upbeat FY26 Operating Income Guidance?

Can CRS Achieve Its Upbeat FY26 Operating Income Guidance?

Carpenter Technology lifts its FY26 operating income outlook after a record third quarter, driven by aerospace and defense demand, pricing, and volume gains.

Zacks | 1 week ago
Carpenter (CRS) Moves to Buy: Rationale Behind the Upgrade

Carpenter (CRS) Moves to Buy: Rationale Behind the Upgrade

Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 week ago
Here's Why Carpenter Technology (CRS) is a Strong Growth Stock

Here's Why Carpenter Technology (CRS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 week ago
Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?

Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?

Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 2 weeks ago
3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)

3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)

Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 2 weeks ago
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice

Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 3 weeks ago
Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?

Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 month ago
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19

Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19

OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.

Zacks | 1 month ago
Loading...
Load More